+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast - 2028

  • PDF Icon

    Report

  • 253 Pages
  • February 2020
  • Region: Global
  • DelveInsight
  • ID: 4985432
UP TO OFF until Dec 31st 2024

The "Major Depressive Disorder (MDD) - Market Insights, Epidemiology, and Market Forecast - 2028" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MDD in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Major Depressive Disorder (MDD) from 2017 to 2028 segmented by seven emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered


  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Major Depressive Disorder (MDD) - Disease Understanding

A major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in the poor quality of life overall decreased productivity and can increase mortality from suicide. Depression does not have a single cause. It can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or another risk.

Social difficulties including stigma, loss of employment, and marital conflict as a result of depression can also occur. Anxiety Posttraumatic Stress Disorder (PTSD), and substance misuse are common co-occurring conditions that may worsen the existing depression and complicate treatment.

The Major Depressive Disorder (MDD) market report gives a thorough understanding of the Major Depressive Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Major Depressive Disorder in the 7MM.

Major Depressive Disorder Epidemiology

The Major Depressive Disorder (MDD) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (12 months prevalent cases of Major Depressive Disorder, age-specific cases of Major Depressive Disorder, gender-specific cases of Major Depressive Disorder, severity-specific cases of Major Depressive Disorder, treatable cases of Major Depressive Disorder, relapsed/refractory cases of Major Depressive Disorder) scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017-2028.

According to the publisher, a total of 12 months of the prevalent population of Major Depressive Disorder in 7 major markets was observed to be 34,011,712 cases in 2017.

Major Depressive Disorder Drug Chapters

This segment of the Major Depressive Disorder report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Antidepressants comprise the treatment market of MDD. The treatment of MDD is segmented on the basis of various phases includes the acute phase, continuation phase, and maintenance phase of treatment. Different types of depression require different treatment. For moderate to more severe depression, Pharmacological treatments are likely to be required, in combination with these other treatments.

Major Depressive Disorder Market Outlook

The Major Depressive Disorder market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs,
drivers and barriers and demand for better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Major Depressive Disorder in 7MM was found to be USD 9.3 Billion in 2017 and is expected to increase during the course of the study period (2017-2028). United States accounts for the largest market size of Major Depressive Disorder, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Major Depressive Disorder Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Major Depressive Disorder Report Insights


  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Major Depressive Disorder Report Key Strengths


  • 9 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Major Depressive Disorder Report Assessment


  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits


  • This report will help to develop Business Strategies by understanding the trends shaping and driving Major Depressive Disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Major Depressive Disorder market
  • To understand the future market competition in the Major Depressive Disorder market.

Table of Contents


1. Key Insights
2. Major Depressive Disorder (MDD) Market Overview at a Glance
2.1. Market Share (%) Distribution of MDD in 2017
2.2. Market Share (%) Distribution of MDD in 2028
3. Disease Overview: Major Depressive Disorder (MDD)
3.1. Introduction
3.2. Sign and Symptoms
3.3. Types of Major Depressive Disorder
3.4. Causes of Major Depressive Disorder
3.5. Pathophysiology of Depression
3.6. Genetic Basis of Major Depressive Disorder
3.7. Biomarkers in MDD
3.8. Diagnosis and Severity
3.8.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total 12 Months Prevalent Patient Population of Major Depressive Disorder
5. Country Wise-Epidemiology of Major Depressive Disorder
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. 12 Months Prevalent Cases of Major Depressive Disorder in the United States
5.1.3. Age-Specific Cases of Major Depressive Disorder in the United States
5.1.4. Gender Specific Cases of Major Depressive Disorder in the United States
5.1.5. Severity Specific Cases of Major Depressive Disorder in the United States
5.1.6. Treatable Cases of Major Depressive Disorder in the United States
5.1.7. Relapse/Refractory Cases of Major Depressive Disorder in the United States
5.2. EU5
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. 12 Months Prevalent Cases of Major Depressive Disorder in Germany
5.3.2. Age-Specific Cases of Major Depressive Disorder in Germany
5.3.3. Gender Specific Cases of Major Depressive Disorder in Germany
5.3.4. Severity Specific Cases of Major Depressive Disorder in Germany
5.3.5. Treatable Cases of Major Depressive Disorder in Germany
5.3.6. Relapse/Refractory Cases of Major Depressive Disorder in Germany
5.4. France
5.4.1. 12 Months Prevalent Cases of Major Depressive Disorder in France
5.4.2. Age-Specific Cases of Major Depressive Disorder in France
5.4.3. Gender Specific Cases of Major Depressive Disorder in France
5.4.4. Severity Specific Cases of Major Depressive Disorder in France
5.4.5. Treatable Cases of Major Depressive Disorder in France
5.4.6. Relapse/Refractory Cases of Major Depressive Disorder in France
5.5. Italy
5.5.1. 12 Months Prevalent Cases of Major Depressive Disorder in Italy
5.5.2. Age-Specific Cases of Major Depressive Disorder in Italy
5.5.3. Gender Specific Cases of Major Depressive Disorder in Italy
5.5.4. Severity Specific Cases of Major Depressive Disorder in Italy
5.5.5. Treatable Cases of Major Depressive Disorder in Italy
5.5.6. Relapse/Refractory Cases of Major Depressive Disorder in Italy
5.6. Spain
5.6.1. 12 Months Prevalent Cases of Major Depressive Disorder in Spain
5.6.2. Age-Specific Cases of Major Depressive Disorder in Spain
5.6.3. Gender Specific Cases of Major Depressive Disorder in Spain
5.6.4. Severity Specific Cases of Major Depressive Disorder in Spain
5.6.5. Treatable Cases of Major Depressive Disorder in Spain
5.6.6. Relapse/Refractory Cases of Major Depressive Disorder in Spain
5.7. United Kingdom
5.7.1. 12 Months Prevalent Cases of Major Depressive Disorder in the UK
5.7.2. Age-Specific Cases of Major Depressive Disorder in the UK
5.7.3. Gender Specific Cases of Major Depressive Disorder in the UK
5.7.4. Severity Specific Cases of Major Depressive Disorder in the UK
5.7.5. Treatable Cases of Major Depressive Disorder in the UK
5.7.6. Relapse/Refractory Cases of Major Depressive Disorder in the UK
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. 12 Months Prevalent Cases of Major Depressive Disorder in Japan
5.8.3. Age-Specific Cases of Major Depressive Disorder in Japan
5.8.4. Gender Specific Cases of Major Depressive Disorder in Japan
5.8.5. Severity Specific Cases of Major Depressive Disorder in Japan
5.8.6. Treatable Cases of Major Depressive Disorder in Japan
5.8.7. Relapse/Refractory Cases of Major Depressive Disorder in Japan
6. Current Treatment Practices
6.1. American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder
6.2. Major Depressive Disorder Treatment Guidelines in the US and Europe
6.3. Guidelines in Spanish SHN for the Management of Major Depression in Adults
6.3.1. Therapeutic algorithm
6.4. Major Depressive Disorder Treatment Guidelines in Japan
6.5. Major depressive disorder -Clinical practice review
6.5.1. Treatment Options for Adults
6.5.2. Treatment Options for Children and Adolescents
6.5.3. Treatment Options for Late-Life (Older Adults)
6.6. Algorithm for the Management of Major Depressive Disorder
6.7. Algorithm for the Pharmacotherapy of MDD
7. Unmet Needs
8. Marketed Drugs
8.1. Key cross competition- Marketed Drugs
8.2. Brintellix: Takeda Pharmaceuticals
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Fetzima: Takeda Pharmaceuticals
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. Rexulti: Otsuka Pharmaceutical
8.4.1. Drug Description
8.4.2. Regulatory Milestones
8.4.3. Clinical Development
8.4.4. Safety and Efficacy
8.4.5. Product Profile
9. Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. AXS-05: Axsome Therapeutics
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. ALKS 5461: Alkermes
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. Travivo: Fabre-Kramer Pharmaceuticals
9.4.1. Product Description
9.4.2. Other Developmental Activities
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. SAGE-217: SAGE Therapeutics
9.5.1. Product Description
9.5.2. Other Developmental Activities
9.5.3. Clinical Development
9.5.4. Safety and Efficacy
9.5.5. Product Profile
9.6. Esketamine nasal spray: Janssen Research & Development
9.6.1. Product Description
9.6.2. Other Development Activities
9.6.3. Clinical Development
9.6.4. Safety and Efficacy
9.6.5. Product Profile
9.7. Cariprazine: Allergan/ Gedeon Richter
9.7.1. Product Description
9.7.2. Other Development Activities
9.7.3. Clinical Development
9.7.4. Safety and Efficacy
9.7.5. Product Profile
9.8. CTC-501: Chase Therapeutics
9.8.1. Product Description
9.8.2. Other Development Activities
9.8.3. Clinical Development
9.8.4. Product profile
9.9. Pimavanserin: ACADIA Pharmaceuticals
9.9.1. Product Description
9.9.2. Clinical Development
9.9.3. Safety and Efficacy
9.9.4. Product Description
9.10. LY03005: Luye Pharma
9.10.1. Product Description
9.10.2. Other Development Activities
9.10.3. Clinical Development
9.10.4. Product Description
9.11. NRX-1074 (Apimostinel): Allergen
9.11.1. Product Description
9.11.2. Other Development Activities
9.11.3. Clinical Development
9.11.4. Product Description
10. Discontinued Late Stage Products
10.1. Rapastinel: Naurex (an affiliate of Allergan)
10.1.1. Product Description
10.1.2. Other Development Activities
10.1.3. Clinical Development
10.1.4. Safety and Efficacy
10.1.5. Product Profile
11. Major Depressive Disorder: 7 Major Market Analysis
11.1.   Key Findings
11.2. Assumptions and Caveats
11.3. Market Size of Major Depressive Disorder in 7MM
12. Market Outlook by Country
13. The United States: Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of Major Depressive Disorder
13.1.2. Major Depressive Disorder Market by Current Therapies
13.1.3. Major Depressive Disorder Market by Emerging Therapies
14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Major Depressive Disorder
14.1.2. Major Depressive Disorder Market by Current Therapies
14.1.3. Major Depressive Disorder Market by Emerging Therapies
14.2. France
14.2.1. Total Market size of Major Depressive Disorder
14.2.2. Major Depressive Disorder Market by Current Therapies
14.2.3. Major Depressive Disorder Market by Emerging Therapies
14.3. Italy
14.3.1. Total Market size of Major Depressive Disorder
14.3.2. Major Depressive Disorder Market by Current Therapies
14.3.3. Major Depressive Disorder Market by Emerging Therapies
14.4. Spain
14.4.1. Total Market size of Major Depressive Disorder
14.4.2. Major Depressive Disorder Market by Current Therapies
14.4.3. Major Depressive Disorder Market by Emerging Therapies
14.5. United Kingdom
14.5.1. Total Market size of Major Depressive Disorder
14.5.2. Major Depressive Disorder Market by Current Therapies
14.5.3. Major Depressive Disorder Market by Emerging Therapies
14.6. Japan: Market Outlook
14.6.1. Total Market size of Major Depressive Disorder
14.6.2. Major Depressive Disorder Market by Current Therapies
14.6.3. Major Depressive Disorder Market by Emerging Therapies
15. Market Drivers16. Market Barriers
17. Appendix
17.1. Report Methodology
18. Capabilities19. Disclaimer20. About the Publisher
List of Tables
Table 1: DSM-IV-TR diagnostic criteria - MDD
Table 2: DSM-IV-TR diagnostic criteria for MDD, Single episode
Table 3: DSM-IV-TR diagnostic criteria for MDD, Recurrent
Table 4: Selected DSM-IV-TR Major Depressive Episode Specifier
Table 5: Major depressive disorder diagnostic criteria according to DSM-V
Table 6: General Diagnostic Criteria of a Depressive episode according to ICD-10
Table 7: Severity Criteria of a Depressive episode according to ICD-10
Table 8: 12 Months Prevalent Patient Population of MDD in the 7MM (2017-2028)
Table 9: 12 months Prevalent Cases of Major Depressive Disorder in the US (2017-2028)
Table 10: Age-Specific Cases of Major Depressive Disorder in the US (2017-2028)
Table 11: Gender Specific Cases of Major Depressive Disorder in the US (2017-2028)
Table 12: Severity Specific Cases of Major Depressive Disorder in the US (2017-2028)
Table 13: Treatable Cases of Major Depressive Disorder in the US (2017-2028)
Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US (2017-2028)
Table 15: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2017-2028)
Table 16: Age-Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Table 17: Gender Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Table 18: Severity Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Table 19: Treatable Cases of Major Depressive Disorder in Germany (2017-2028)
Table 20: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2017-2028)
Table 21: 12 Months Prevalent Cases of Major Depressive Disorder in France (2017-2028)
Table 22: Age-Specific Cases of Major Depressive Disorder in France (2017-2028)
Table 23: Gender Specific Cases of Major Depressive Disorder in France (2017-2028)
Table 24: Severity Specific Cases of Major Depressive Disorder in France (2017-2028)
Table 25: Treatable Cases of Major Depressive Disorder in France (2017-2028)
Table 26: Relapse/Refractory Cases of Major Depressive Disorder in France (2017-2028)
Table 27: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2017-2028)
Table 28: Age-Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Table 29: Gender Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Table 30: Severity Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Table 31: Treatable Cases of Major Depressive Disorder in Italy (2017-2028)
Table 32: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2017-2028)
Table 33: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2017-2028)
Table 34: Age-Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Table 35: Gender Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Table 36: Severity Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Table 37: Treatable Cases of Major Depressive Disorder in Spain (2017-2028)
Table 38: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2017-2028)
Table 39: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2017-2028)
Table 40: Age-Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Table 41: Gender Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Table 42: Severity Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Table 43: Treatable Cases of Major Depressive Disorder in the UK (2017-2028)
Table 44: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2017-2028)
Table 45: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2017-2028)
Table 46: Age-Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Table 47: Gender Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Table 48: Severity Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Table 49: Treatable Cases of Major Depressive Disorder in Japan (2017-2028)
Table 50: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2017-2028)
Table 51: Key Cross Competition- Marketed Drugs
Table 52: Vortioxetine, Clinical Trial Description, 2019
Table 53: Levomilnacipran, Clinical Trial Description, 2019
Table 54: Rexulti, Clinical Trial Description, 2019
Table 55: Key Cross Competition - Emerging Therapies
Table 56: AXS-05, Clinical Trial Description, 2019
Table 57: ALKS 5461, Clinical Trial Description, 2019
Table 58: SAGE-217, Clinical Trial Description, 2019
Table 59: Esketamine Nasal Spray, Clinical Trial Description, 2019
Table 60: Cariprazine, Clinical Trial Description, 2019
Table 61: Rapastinel , Clinical Trial Description, 2019
Table 62: 7 Major Market Size of Major Depressive Disorder in USD Billion (2017-2028)
Table 63: United States Market Size of MDD in USD Billion (2017-2028)
Table 64: United States Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 65: United States Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 66: Germany Market Size of MDD in USD Billions (2017-2028)
Table 67: Germany Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 68: Germany Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 69: France Market Size of MDD in USD Billions (2017-2028)
Table 70: France Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 71: France Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 72: Italy Market Size of MDD in USD Billions (2017-2028)
Table 73: Italy Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 74: Italy Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 75: Spain Market Size of MDD in USD Billions (2017-2028)
Table 76: Spain Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 77: Spain Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 78: UK Market Size of MDD in USD Billions (2017-2028)
Table 79: UK Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 80: UK Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Table 81: Japan Market Size of MDD in USD Billions (2017-2028)
Table 82:Japan Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Table 83:Japan Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
List of Figures
Figure 1: Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder
Figure 2: 12 Months Prevalent Patient Population of MDD in the 7MM (2017-2028)
Figure 3: 12 Months Prevalent Cases of Major Depressive Disorder in the US (2017-2028)
Figure 4: Age-Specific Cases of Major Depressive Disorder in the US (2017-2028)
Figure 5: Gender Specific Cases of Major Depressive Disorder in the US (2017-2028)
Figure 6: Severity Specific Cases of Major Depressive Disorder in the US (2017-2028)
Figure 7: Treatable Cases of Major Depressive Disorder in the US (2017-2028)
Figure 8: Relapse/Refractory Cases of Major Depressive Disorder in the US (2017-2028)
Figure 9: 12 Months Prevalent Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 10: Age-Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 11: Gender Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 12: Severity Specific Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 13: Treatable Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 14: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2017-2028)
Figure 15: 12 Months Prevalent Cases of Major Depressive Disorder in France (2017-2028)
Figure 16: Age-Specific Cases of Major Depressive Disorder in France (2017-2028)
Figure 17: Gender Specific Cases of Major Depressive Disorder in France (2017-2028)
Figure 18: Severity Specific Cases of Major Depressive Disorder in France (2017-2028)
Figure 19: Treatable Cases of Major Depressive Disorder in France (2017-2028)
Figure 20: Relapse/Refractory Cases of Major Depressive Disorder in France (2017-2028)
Figure 21: 12 Months Prevalent Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 22: Age-Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 23: Gender Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 24: Severity Specific Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 25: Treatable Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2017-2028)
Figure 27: 12 Months Prevalent Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 28: Age-Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 29: Gender Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 30: Severity Specific Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 31: Treatable Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 32: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2017-2028)
Figure 33: 12 Months Prevalent Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 34: Age-Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 35: Gender Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 36: Severity Specific Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 37: Treatable Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 38: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2017-2028)
Figure 39: 12 Months Prevalent Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 40: Age-Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 41: Gender Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 42: Severity Specific Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 43: Treatable Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 44: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2017-2028)
Figure 45: Basic Principles of Depression Treatment in American and European Guidelines
Figure 46: Japanese Treatment Algorithm for Mild-Moderate Major Depression
Figure 47: Unmet Needs for Major Depressive Disorder
Figure 48: 7 Major Market Size of Major Depressive Disorder in USD Billion (2017-2028)
Figure 49: United States Market Size of MDD in USD Billion (2017-2028)
Figure 50: United States Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 51: United States Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 52: Germany Market Size of MDD in USD Billions (2017-2028)
Figure 53: Germany Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 54: Germany Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 55: France Market Size of MDD in USD Billions (2017-2028)
Figure 56: France Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 57: France Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 58: Italy Market Size of MDD in USD Billions (2017-2028)
Figure 59: Italy Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 60: Italy Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 61: Spain Market Size of MDD in USD Billions (2017-2028)
Figure 62: Spain Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 63: Spain Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 64: UK Market Size of MDD in USD Billions (2017-2028)
Figure 65: UK Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 66: UK Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 67: Japan Market Size of MDD in USD Billions (2017-2028)
Figure 68: Japan Market Size of MDD by Current Therapies in USD Billion (2017-2028)
Figure 69: Japan Market Size of MDD by Emerging Therapies in USD Billion (2017-2028)
Figure 70: Market Drivers
Figure 71: Market Barriers

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ACADIA Pharmaceuticals
  • Alkermes
  • Allergen
  • Axsome Therapeutics
  • BlackThorn Therapeutics
  • Chase Therapeutics
  • Fabre-Kramer Pharmaceuticals
  • Gedeon Richter
  • Janssen Pharmaceuticals
  • Lundbeck A/S
  • Luye Pharma
  • Minerva Neurosciences
  • Otsuka Pharmaceutical
  • Pfizer
  • SAGE Therapeutics
  • Takeda Pharmaceuticals